
Recursion Reports Third Quarter 2025 Financial Results and Provides ...
Nov 5, 2025 · Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Montréal, New York, London, …
Pioneering AI Drug Discovery | Recursion
All of our results feed back into our drug discovery and drug development platform – the Recursion Operating System – in a continuously improving feedback loop.
Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc. - Recursion and Exscientia Enter ...
Aug 8, 2024 · Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Toronto, Montreal, the San …
How a First-of-its-Kind “Microglia Map” from Recursion and Roche and ...
Oct 29, 2025 · A first-of-its-kind whole genome map from researchers at Recursion with partners Roche and Genentech offers a new approach to exploring novel targets and pathways for a wide range of …
Models - portfolio.recursion.com
Dive into an interactive experience with our pipeline, partners and models.
Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias.
Recursion Pharmaceuticals, Inc. - Recursion Announces Webinar For ...
Dec 1, 2025 · Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by …
Partners - Recursion
In May 2024, Recursion entered into a multi-year agreement with Helix to access hundreds of thousands of de-identified records including Helix’s Exome+® genomic data and data from longitudinal health …
Recursion's Drug Discovery Pipeline | Recursion
Leveraging the power of the Recursion OS, we are building an industry-leading pipeline of potential best-in-class and first-in-class therapeutic assets. We focus on indications with high unmet need, …